智通财经网·2025-09-09 02:13Core Viewpoint - Junshi Biosciences (01877) experienced a significant stock increase of over 9%, with a current price of HKD 38.36 and a trading volume of HKD 173 million, following the positive results of its clinical trial for JS005, a monoclonal antibody targeting IL-17A in treating moderate to severe plaque psoriasis [1]. Group 1: Clinical Trial Results - The company announced that its product, JS005, achieved positive results in a pivotal Phase III clinical trial (Study No: JS005-005-III-PsO) for treating moderate to severe plaque psoriasis, meeting both primary and key secondary endpoints with statistical significance and clinical relevance [1]. - The trial demonstrated that JS005 significantly improved the psoriasis lesion area and severity compared to the placebo, with a notably higher proportion of participants achieving a sPGA score of 0 or 1 [1]. - The safety profile of JS005 was found to be good among participants with moderate to severe plaque psoriasis, and the results are planned to be presented at an upcoming international academic conference [1]. Group 2: Regulatory Plans - The company plans to submit a marketing authorization application for JS005 to regulatory authorities in the near future [1].